{
    "clinical_study": {
        "@rank": "51814", 
        "brief_summary": {
            "textblock": "Aim of this in vitro trial is to assess the effect on blood coagulation after 60 % dilution\n      with different colloids (HES 130/0.42, Gelatin and Gelatin balanced) and investigate\n      reversibility by replacement of fibrinogen (FBG), factor XIII (F XIII), and the combination\n      of FBG and FXIII.\n\n      In blood of 12 volunteers the following measurements are performed at baseline and 60%\n      dilution with HES 130/0.42, Gelatin or Gelatin balanced: Blood gas analyses, coagulation\n      factor concentrations (F II,F VII,F VIII,F XIII), impedance aggregometry and rotational\n      thrombelastometry (ROTEM\u00ae). Then FBG, F XIII and a combination of both was added, in\n      concentrations corresponding to 6 g FBG and 1250 IU F XIII in adults. ROTEM\u00ae measurements\n      and determination of factor concentrations are again performed.\n\n        -  Trial with medical device"
        }, 
        "brief_title": "Hemodilution and Coagulopathy With 3 Colloids", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Dilutional Coagulopathy", 
        "condition_browse": {
            "mesh_term": [
                "Blood Coagulation Disorders", 
                "Hemostatic Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  signed informed consent from before blood withdrawal\n\n        Exclusion criteria:\n\n          -  known coagulation disorders,\n\n          -  any form of anticoagulation therapy,\n\n          -  use of acetyl-salicylic acid within the past five days,\n\n          -  use of non-steroidal anti-inflammatory agents within the past 24 hours,\n\n          -  known renal disease or plasma concentrations of aspartate aminotransferase (>50 U l\n             -1) or alanine aminotransferase (>50 U l-1)\n\n          -  patients incapable of understanding the German language"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "volunteers"
            }
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01727830", 
            "org_study_id": "KEK-ZH-Nr. 2012-0042"
        }, 
        "intervention": {
            "description": "Blood drawn from volunteers", 
            "intervention_name": "Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)", 
            "intervention_type": "Other", 
            "other_name": [
                "This trial is in vitro and made with blood of healthy volunteers.", 
                "Thus no drug no intervention beside drawing blood is beeing performed."
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 12, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "state": "ZH", 
                    "zip": "8091"
                }, 
                "name": "University Hospital Zurich, Division of Anaesthesiology"
            }
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_groups": "1", 
        "official_title": "Influence of Hemodilution on Coagulation, pH, Platelet Function, Laboratory Values and ROTEM in Volunteers Using HES 6%, Gelatine and Balanced Gelatine and the Reversal of Coagulopathy With F XIII and Fibrinogen", 
        "overall_official": {
            "affiliation": "University Hospital Zurich, Division of Anaesthesiology", 
            "last_name": "Oliver Theusinger, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Coagulopathy in vitro measured after 60 % dilution with HES, Gelatin and Gelatin balanced. Addition of fibrinogen and factor XIII as well as their combination and measurement if the coagulopathy was corrected.", 
            "measure": "Reversibility of in vitro induced coagulopathy", 
            "safety_issue": "Yes", 
            "time_frame": "Same day when blood was drawn"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01727830"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2012"
    }
}